Although higher EREG expression in the tumor foci is correlated with lower survival rate of posttreatment cancer patients (Fig. 2I and Supplementary Fig. 2I), whether blood-borne EREG is technically detectable and can be used as a marker for clinical prediction remains unclear. This evidence concerns the gene EREG and neoplasm.